Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The latest edition of this essential text provides a comprehensive overview of the unique pediatric issues of inflammatory bowel disease. Through new and thoroughly revised chapters, the volume features updates on all aspects of etiology, diagnosis, and treatment, with an emphasis on recent understanding of pharmacokinetics and the utilization of cutting edge therapeutic monitoring to maximize efficacy of medical management. The new edition also highlights newer, recently approved drugs, emerging therapies, and the most recent recommendations regarding post-operative management for patients who ultimately require surgery. Written by experts in the field, Pediatric Inflammatory Bowel Disease, Fourth Edition is a valuable resource for both pediatric and adult gastroenterologists involved in the care of children with inflammatory bowel disease. .

Inflammatory bowel diseases. --- Pediatric gastroenterology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Inflammatory bowel diseases. --- Affections intestinales inflammatoires

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Inflammatory bowel diseases --- Inflammatory Bowel Diseases. --- Inflammatory bowel diseases. --- IBD (Disease) --- Inflammatory bowel disease --- Intestines --- Bowel Diseases, Inflammatory --- Inflammatory Bowel Disease --- Inflammation --- Gastroenteritis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is intended to act as an up to date reference point and knowledge developer for all readers interested in the area of gastroenterology and in particular Ulcerative Colitis. All of the chapter authors are experts in their fields of publication and deserve individual credit and praise for their contributions to the world of Ulcerative Colitis. We hope that you will find this publication informative, stimulating and a reference point for the area of Ulcerative colitis as we move forward in our understanding of the field of medicine.

Ulcerative colitis --- Treatment. --- Colitis --- Inflammatory bowel diseases --- Hepatology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Background Patients with the inflammatory bowel diseases ulcerative colitis and Crohn's disease need lifelong treatment and care. Effect of traditional treatments is varied and may cause serious adverse events. Biological drugs aimed at blocking specific molecular steps in the inflammatory process have been developed. Tumor necrosis factor (TNF)α is a proinflammatory cytokine with a role in the inflammatory process associated with inflammatory bowel disease. Hence, a drug blocking this cytokine might be useful for patients with ulcerative colitis and Crohn's disease. This report includes knowledge of the TNFα-inhibitors infliximab (Remicade(r)), adalimumab (Humira(r)), etanercept (Enbrel(r)) and certolizumab pegol (Cimzia(r)). Method We systematically reviewed and critically appraised available documentation on effect and safety of TNFα-inhibitors. In addition, we have reviewed health economic studies. We identified documentation by a systematic search in Cochrane Library, Medline, Embase, PubMed and NHS Economics Evaluation Database. Our evaluation on efficacy and safety was based on systematic reviews. However, to make sure that all available data was included, we searched for randomized controlled trials published afer the literature seach in the systematic reviews was performed. Results In patients with ulcerative colitis, infliximab was more effective than placebo in achieving improvement of the disease. Data on response and remission are available up to 54 weeks. Infliximab gives a higer proportion of patients with endoscopic remission compared to placebo. None of the other TNFα-inhibitors were tested in patients with ulcerative colitis. In patients with Crohn's disease, infliximab, adalimumab and certolizumab were more effective than placebo in achieving response after induction treatment (1-3 administrations of drug or placebo). Based on patients responding to induction treatment, it has been shown that maintenance treatment with infliximab, adalimumab and certolizumab is more effective than placebo in maintaining the initial response. Infliximab has been showed to be more effective than placebo in achieving fistula closure. Data on etanercerpt in treatment of Crohn's disease is limited. There is no basis to claim that etanercerpt has effect in treatment of Crohn's disease. We identified four economic evaluations in a systematic literature search. All studies were from countries outside Norway and dealt with infliximab treatment of patients with Crohn's disease. Conclusion Infliximab is effective in treatment of ulcerative colitis and Crohn's disease. Adalimumab and certolizumab have documented effect in treatment of Crohn's disease, while studies on patients with ulcerative colitis are lacking. There is too limited data available to conclude regarding safety of long-term treatment with TNFα-inhibitors for both ulcerative colitis and Crohn's disease. Based on results from countries outside Norway, infliximab does not seem to be cost-effective as continuous treatment for patients with Crohn's disease. There might be an exception in the case of patients exhibiting good and long-lasting response. No relevant economic studies were found for ulcerative colitis or for the other TNFα-inhibitors.

Tumor necrosis factor. --- Inflammatory bowel diseases --- Anti-inflammatory agents. --- Treatment.